An Open-Label, Multicenter Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients With Relapsing Multiple Sclerosis Receiving Treatment With Ocrelizumab

– Diagnosis of RMS with Expanded Disability Status Scale (EDSS) 0-5.5 at enrollment

– Participants who self-identify as African American or Hispanic/Latino American

– Treatment-naïve or initiating first switch from receiving treatment with certain
disease modifying therapies (DMTs) including interferon or glatiramer acetate or
dimethylfumarate (DMF); or siponimod; or fingolimod

– Disease duration from the onset of MS symptoms: less than 15 years in participants
with an EDSS >5.0 at screening

– At least one clinically documented episode (for naïve participants) or suboptimal
response or intolerance to prior DMT (for switch participants) in the past year and/or
at least one T1-weighted Gd-enhancing lesion in the past year and/or at least one new
or expanding T2 lesion in the past year at the time of enrollment

– For women of childbearing potential: agreement to remain abstinent (refrain from
heterosexual intercourse) or use acceptable contraceptive methods during the treatment
period and for 6 months after the final dose of ocrelizumab

Exclusion Criteria:

– Diagnosis of secondary progressive MS without relapses for at least 1 year

– Primary Progressive Multiple Sclerosis (PPMS)

– Known presence of recurrent or chronic infection (e.g., HIV, syphilis, tuberculosis)

– History of recurrent aspiration pneumonia requiring antibiotic therapy

– History or known presence of infectious causes of myelopathy (e.g., syphilis, Lyme
disease, HTLV-1, herpes zoster myelopathy)

– Known active bacterial, viral, fungal, mycobacterial infection, or other infection or
any major episode of infection requiring hospitalization or treatment with IV
antibiotics within 4 weeks prior to baseline visit or oral antibiotics within 2 weeks
prior to baseline visit

– History of cancer, including solid tumors and hematological malignancies

– Pregnant or lactating, or intending to become pregnant during the study

– History of or currently active primary or secondary immunodeficiency

– History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
antibodies

– History or known presence of systemic autoimmune disorders

– Any concomitant disease that may require chronic treatment with systemic
corticosteroids or immunosuppressants during the course of the study

– Significant, uncontrolled disease including congestive heart failure, uncontrolled
hypertension, pulmonary, renal, hepatic, endocrine, gastrointestinal, or any other
significant disease

– Known presence or history of other neurologic disorders

– Prior treatment with any disease modifying therapy for MS other than interferon or
glatiramer acetate or dimethylfumarate (DMF); or siponimod; or fingolimod

– Previous treatment with cyclophosphamide, mitoxantrone, azathioprine, mycophenolate
mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow
transplantation

– Previous or concurrent treatment with any investigational agent or treatment with any
experimental procedure for MS

– History of alcohol or other drug abuse within 24 weeks prior to enrollment

– Vaccinations

– Certain laboratory abnormalities or findings at Screening